California State Teachers Retirement System Increases Stock Position in CRISPR Therapeutics AG $CRSP

Key Points

• California State Teachers Retirement System increased its CRISPR Therapeutics stake by 29.6% in the first quarter, acquiring 23,109 additional shares and bringing its holdings to 101,232 shares valued at approximately $4.8 million.
• CRISPR Therapeutics continues to attract institutional and analyst interest, with 69.2% of shares held by institutions and a consensus “Moderate Buy” rating with a $68.06 price target.
• The company remains unprofitable, with analysts forecasting a current-year loss of $4.65 per share, although potential growth from CASGEVY and the CTX310 in vivo gene-editing program supports the long-term investment case.

California State Teachers Retirement System raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 29.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,232 shares of the company's stock after acquiring an additional 23,109 shares during the period. California State Teachers Retirement System owned 0.10% of CRISPR Therapeutics worth $4,816,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in CRSP. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $26,000. Rothschild Investment LLC grew its position in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company's stock worth $29,000 after purchasing an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company's stock worth $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Oakworth Capital Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $34,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the firm's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares of the company's stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.20% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $51.64 on Friday. The company has a current ratio of 17.85, a quick ratio of 17.96 and a debt-to-equity ratio of 0.34. The stock's 50 day moving average is $52.42 and its two-hundred day moving average is $52.30. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $78.48. The firm has a market capitalization of $4.99 billion, a PE ratio of -10.85 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The business had revenue of $10.18 million for the quarter. Research analysts anticipate that CRISPR Therapeutics AG will post -4.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several recent research reports. Evercore reiterated an "outperform" rating and set a $76.00 target price on shares of CRISPR Therapeutics in a research note on Monday, May 11th. Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. Citizens Jmp reaffirmed a "market outperform" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, July 6th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Finally, UBS Group set a $80.00 target price on CRISPR Therapeutics in a report on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $68.06.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source